November 11, 2024
1 min watch
Save
VIDEO: Ocular Therapeutix shifts to retina-focused treatments
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.
Two phase 3 macular degeneration programs investigating Axpaxli, a sustained-release polymer that delivers a tyrosine kinase inhibitor, are underway at Ocular Therapeutix.
“Early studies in macular degeneration as well as diabetic retinopathy have been very promising,” Kaiser said.
Published by:
Sources/Disclosures
Collapse
Source:
Kaiser P. AAO 2024 retina showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago.
Disclosures:
Kaiser reports being the chief development officer at Ocular Therapeutix.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.